[1]万文萃,龙洋.糖尿病视网膜病变的流行病学、病因学与发病机制研究现状[J].眼科新进展,2022,42(9):673-679.[doi:10.13389/j.cnki.rao.2022.0138]
　WAN Wencui,LONG Yang.Research status of epidemiology,etiology and pathogenesis of diabetic retinopathy[J].Recent Advances in Ophthalmology,2022,42(9):673-679.[doi:10.13389/j.cnki.rao.2022.0138]
点击复制

糖尿病视网膜病变的流行病学、病因学与发病机制研究现状/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年9期
页码:
673-679
栏目:
述评
出版日期:
2022-09-05

文章信息/Info

Title:
Research status of epidemiology,etiology and pathogenesis of diabetic retinopathy
作者:
万文萃; 龙洋
450052　河南省郑州市，郑州大学第一附属医院眼二科（万文萃）；710004　陕西省西安市，西安市人民医院（西安市第四医院），陕西省眼科医院（龙洋）
Author(s):
WAN Wencui1; LONG Yang2
1.Department of Ophthalmology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan Province,China
2.Xi’an People’s Hospital (Xi’an Fourth Hospital),Shaanxi Eye Hospital,Xi’an 710004,Shaanxi Province,China
关键词:
糖尿病视网膜病变; 流行病学; 病因学; 发病机制
Keywords:
diabetic retinopathy;  epidemiology;  etiology;  pathogenesis
分类号:
R774
DOI:
10.13389/j.cnki.rao.2022.0138
文献标志码:
A
摘要:
糖尿病视网膜病变(DR）是全球工作年龄人群视力丧失的主要原因，根据国际糖尿病地图研究预测，2045年中国糖尿病患者将达1.74亿， DR 正在成为全球公共卫生问题。本文就DR的流行病学、病因学、发病机制作一阐述，从DR的流行病学推测疾病将来会波及的人群数量，提醒我们要高度重视本病的预防。从糖尿病的病程发展推测可能的病因学，从氧化应激等反应来研究DR的发病机制，以便开发可靠和有力的手段识别高风险患者，并在视力丧失发生之前进行有效干预。
Abstract:
Diabetic retinopathy (DR) is the main cause of diabetes-related vision loss in the working-age population worldwide. According to the IDF Diabetes Atlas, it is predicted that there will be 174 million diabetic patients in China by 2045. DR is becoming a global public health challenge. In this paper, the epidemiology, etiology, and pathogenesis of DR are described, and the number of people who will be affected by the disease in the future is estimated from the epidemiology of DR, calling our attention to the prevention of this disease. The possible etiology is explored from the progression of diabetes, and the pathogenesis of DR is investigated from oxidative stress and other reactions, in order that reliable and robust means can be developed to identify high-risk patients and intervene effectively before vision loss occurs.

参考文献/References:

［1］　TEO Z L,YC T,YU M,CHEE M L,RIM T H,CHEUNG N,et al.Global prevalence of diabetic retinopathy and projection of burden through 2045:systematic review and meta-analysis［J］.Ophthalmology,2021,128(11):1580-1591.
［2］　SUN H,SAEEDI P,KARURANGA S,PINKEPANK M,OGURTSOVA K,DUNCAN B B,et al.IDF diabetes atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045［J］.Diabetes Res Clin Pract,2022,183:109119.
［3］　FLAXEL C J,ADELMAN R A,BAILEY S T,FAWZI A,LIM J I,VEMULAKONDA G A,et al.Diabetic retinopathy preferred practice pattern?［J］.Ophthalmology,2020,127(1):P66-P145.
［4］　CHEUNG N,MITCHELL P,WONG T Y.Diabetic retinopathy［J］.Lancet,2010,376(9735):124-136.
［5］　FLAXMAN S R,BOURNE R R,RESNIKOFF S,ACKLAND P,BRAITHWAITE T,CICINELLI M V,et al.Global causes of blindness and distance vision impairment 1990-2020:a systematic review and meta-analysis［J］.Lancet Glob Health,2017,5(12):e1221-e1234.
［6］　KEMPEN J H,O’COLMAIN B J,LESKE M C,HAFFNER S M,KLEIN R,MOSS S E,et al.The prevalence of diabetic retinopathy among adults in the United States［J］.Arch Ophthalmol,2004,122(4):552-563.
［7］　ZHANG X,SAADDINE J B,CHOU C F,COTCH M F,CHENG Y J,GEISS L S,et al.Prevalence of diabetic retinopathy in the United States,2005-2008［J］.JAMA,2010,304(6):649-656.
［8］　NAGDA D,MITCHELL W,ZEBARDAST N.The functional burden of diabetic retinopathy in the United States［J］.Graefes Arch Clin Exp Ophthalmol,2021,259(10):2977-2986.
［9］　LI J Q,WELCHOWSKI T,SCHMID M,LETOW J,WOLPERS C,PASCUAL-CAMPS I,et al.Prevalence,incidence and future projection of diabetic eye disease in Europe:a systematic review and meta-analysis［J］.Eur J Epidemiol,2020,35(1):11-23.
［10］　SONG P,YU J,CHAN K Y,THEODORATOU E,RUDAN I.Prevalence,risk factors and burden of diabetic retinopathy in China:a systematic review and meta-analysis［J］.J Glob Health,2018,8(1):010803.
［11］　ZHANG G H,CHEN H Y,CHEN W Q,ZHANG M Z.Prevalence and risk factors for diabetic retinopathy in China:a multi-hospital-based cross-sectional study［J］.Br J Ophthalmol,2017,101(12):1591-1595.
［12］　LIU Y,SONG Y,TAO L,QIU W,LV H,JIANG X,et al.Prevalence of diabetic retinopathy among 13 473 patients with diabetes mellitus in China:a cross-sectional epidemiological survey in six provinces［J］.BMJ Open,2017,7(1):e013199.
［13］　LIN K D,HSU C C,OU H Y,WANG C Y,CHIN M C,SHIN S J.Diabetes-related kidney,eye,and foot disease in Taiwan:an analysis of nationwide data from 2005 to 2014［J］.J Formos Med Assoc,2019,118(Suppl 2):S103-S110.
［14］　SONG S J,HAN K,CHOI K S,KO S H,RHEE E J,PARK C Y,et al.Trends in diabetic retinopathy and related medical practices among type 2 diabetes patients:results from the national insurance service survey 2006-2013［J］.J Diabetes Investig,2018,9(1):173-178.
［15］　WONG T Y,CHEUNG N,TAY W T,WANG J J,AUNG T,SAW S M,et al.Prevalence and risk factors for diabetic retinopathy:the Singapore Malay Eye Study［J］.Ophthalmology,2008,115(11):1869-1875.
［16］　NASERRUDIN N A,JEFFREE M S,KAUR N,SYED A S,IBRAHIM M Y.Correction:diabetic retinopathy among type 2 diabetes mellitus patients in Sabah primary health clinics-addressing the underlying factors［J］.PLoS One,2022,17(2):e0264247.
［17］　YAU J W,ROGERS S L,KAWASAKI R,LAMOUREUX E L,KOWALSKI J W,BEK T,et al.Global prevalence and major risk factors of diabetic retinopathy［J］.Diabetes Care,2012,35(3):556-564.
［18］　TAKAO T,SUKA M,YANAGISAWA H,KASUGA M.Combined effect of diabetic retinopathy and diabetic kidney disease on all-cause,cancer,vascular and non-cancer non-vascular mortality in patients with type 2 diabetes:a real-world longitudinal study［J］.J Diabetes Investig,2020,11(5):1170-1180.
［19］　VARMA R,BRESSLER N M,DOAN Q V,GLEESON M,DANESE M,BOWER J K,et al.Prevalence of and risk factors for diabetic macular edema in the United States［J］.JAMA Ophthalmol,2014,132(11):1334-1340.
［20］　VARMA R.From a population to patients:the Wisconsin epidemiologic study of diabetic retinopathy［J］.Ophthalmology,2008,115(11):1857-1858.
［21］　KLEIN R,KLEIN B E,MOSS S E,CRUICKSHANKS K J.The Wisconsin epidemiologic study of diabetic retinopathy.XIV.ten-year incidence and progression of diabetic retinopathy［J］.Arch Ophthalmol,1994,112(9):1217-1228.
［22］　LECAIRE T J,PALTA M,KLEIN R,KLEIN B E,CRUICKSHANKS K J.Assessing progress in retinopathy outcomes in type 1 diabetes:comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of diabetic retinopathy［J］.Diabetes Care,2013,36(3):631-637.
［23］　LEE R,WONG T Y,SABANAYAGAM C.Epidemiology of diabetic retinopathy,diabetic macular edema and related vision loss［J］.Eye Vis (Lond),2015,2:17.
［24］　SAADANE A,DU Y,THORESON W B,MIYAGI M,LESSIEUR E M,KISER J,et al.Photoreceptor cell Calcium dysregulation and calpain activation promote pathogenic photoreceptor oxidative stress and inflammation in prodromal diabetic retinopathy［J］.Am J Pathol,2021,191(10):1805-1821.
［25］　RAHMAN W,RAHMAN F Z,YASSIN S,AL-SULEIMAN S A,RAHMAN J.progression of retinopathy during pregnancy in type 1 diabetes mellitus［J］.Clin Exp Ophthalmol,2007,35(3):231-236.
［26］　The Diabetes Control and Complications Trial Research Group.Effect of pregnancy on microvascular complications in the diabetes control,TRIAL C ［J］.Diabetes Care,2000,23(8):1084-1091.
［27］　VARMA R,TORRES M,PEA F,KLEIN R,AZEN S P,Los Angeles Latino Eye Study Group.Prevalence of diabetic retinopathy in adult Latinos:the Los Angeles Latino eye study［J］.Ophthalmology,2004,111(7):1298-1306.
［28］　HIRAI F E,KNUDTSON M D,KLEIN B E,KLEIN R.Clinically significant macular edema and survival in type 1 and type 2 diabetes［J］.Am J Ophthalmol,2008,145(4):700-706.
［29］　WEST S K,KLEIN R,RODRIGUEZ J,MUOZ B,BROMAN A T,SANCHEZ R,et al.Diabetes and diabetic retinopathy in a Mexican-American population:proyecto VER［J］.Diabetes Care,2001,24(7):1204-1209.
［30］　HAINSWORTH D P,BEBU I,AIELLO L P,SIVITZ W,GUBITOSI-KLUG R,MALONE J,et al.Risk factors for retinopathy in type 1 diabetes:the DCCT/EDIC study［J］.Diabetes Care,2019,42(5):875-882.
［31］　SONG K H,JEONG J S,KIM M K,KWON H S,BAEK K H,KO S H,et al.Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus［J］.J Diabetes Investig,2019,10(3):745-752.
［32］　CHARLOT A,BAUDIN F,TESSIER M,LEBRIZE S,HURAND V,MEGROIAN D,et al.Mobile telemedicine screening for diabetic retinopathy using nonmydriatic fundus photographs in burgundy:11 years of results［J］.J Clin Med,2022,11(5):1318.
［33］　LU J,MA X,ZHANG L,MO Y,YING L,LU W,et al.Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes［J］.J Diabetes Investig,2019,10(3):753-759.
［34］　PAN C W,WANG S,XU C L,SONG E.Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus［J］.Diabetol Metab Syndr,2018,10(1):73.
［35］　TAKAO T,TAKAHASHI K,YOSHIDA Y,KUSHIYAMA A,ONISHI Y,TAHARA T,et al.Effect of postprandial hyperglycemia at clinic visits on the incidence of retinopathy in patients with type 2 diabetes:an analysis using real-world long-term follow-up data［J］.J Diabetes Investig,2020,11(4):930-937.
［36］　WHITE N H,SUN W,CLEARY P A,DANIS R P,DAVIS M D,HAINSWORTH D P,et al.Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus:10 years after the diabetes control and complications Trial［J］.Arch Ophthalmol,2008,126(12):1707-1715.
［37］　TESTA R,BONFIGLI A R,PRATTICHIZZO F,LA SALA L,DE NIGRIS V,CERIELLO A.The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications［J］.Nutrients,2017,9(5):437.
［38］　The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial ［J］.Diabetes,1995,44(8):968-983.
［39］　RICHARDSON P,HULPUS A,IDRIS I.Short-term impact of bariatric surgery on best-corrected distance visual acuity and diabetic retinopathy progression［J］.Obes Surg,2018,28(11):3711-3713.
［40］　Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group,LACHIN J M,WHITE N H,HAINSWORTH D P,SUN W,CLEARY P A,et al.Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes:18 years of follow-up in the DCCT/EDIC［J］.Diabetes,2015,64(2):631-642.
［41］　SHIBESHI M S,FANTAHUN B,KEBEDE T,TILAHUN B.Pediatric diabetic retinopathy:experience of a tertiary hospital in Ethiopia［J］.BMC Res Notes,2016,9:116.
［42］　LIU L,QUANG N D,BANU R,KUMAR H,THAM Y C,CHENG C Y,et al.Hypertension,blood pressure control and diabetic retinopathy in a large population-based study［J］.PLoS One,2020,15(3):e0229665.
［43］　EMDIN C A,RAHIMI K,NEAL B,CALLENDER T,PERKOVIC V,PATEL A.Blood pressure lowering in type 2 diabetes a systematic review and meta-analysis［J］.JAMA,2015,313(6):603-615.
［44］　TURNER R,HOLMAN R,STRATTON I,CULL C,FRIGHI V,MANLEY S,et al.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38［J］.BMJ,1998,317(7160):703-713.
［45］　CHO A,PARK H C,LEE Y K,SHIN Y J,BAE S H,KIM H.Progression of diabetic retinopathy and declining renal function in patients with type 2 diabetes［J］.J Diabetes Res,2020,2020:8784139.
［46］　CAI X,CHEN Y,YANG W,GAO X,HAN X,JI L.The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes:a meta-analysis［J］.Endocrine,2018,62(2):299-306.
［47］　CHEN J,WAN Y,SU J,ZHU Z,PAN E,SHEN C,et al.Association of generalized and abdominal obesity with diabetic retinopathy in Chinese type 2 diabetic patients［J］.Acta Diabetol,2022,59(3):359-367.
［48］　SHAN Y,WANG Q,ZHANG Y,TONG X,PU S,XU Y,et al.High remnant cholesterol level is relevant to diabetic retinopathy in type 2 diabetes mellitus［J］.Lipids Health Dis,2022,21(1):12.
［49］　KAJIWARA A,MIYAGAWA H,SARUWATARI J,KITA A,SAKATA M,KAWATA Y,et al.Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus:a clinic-based retrospective longitudinal study［J］.Diabetes Res Clin Pract,2014,103(3):e7-10.
［50］　ALSAWAHLI H,MPYET C D,EZZELARAB G,HASSANIN I,SHALABY M,SAFA O,et al.Population-based cross-sectional prevalence survey of diabetes and diabetic retinopathy in Sohag-Egypt,2019［J］.BMJ Open,2021,11(6):e047757.
［51］　YIN L,ZHANG D,REN Q,SU X,SUN Z.Prevalence and risk factors of diabetic retinopathy in diabetic patients:a community based cross-sectional study［J］.Medicine (Baltimore),2020,99(9):e19236.
［52］　WM A,GHANCHI F,BAILEY C,BANERJEE S,BANERJEE SAD-EYE CLINIC U H,DOWNEY L,et al.Diabetic retinopathy and diabetic macular oedema pathways and management:UK Consensus Working Group［J］.Eye (Lond),2020,34(Suppl 1):1-51.
［53］　WAN W C,LONG Y,WAN W W,LIU H Z,ZHANG H H,ZHU W.Plasma melatonin levels in patients with diabetic retinopathy secondary to type 2 diabetes［J］.World J Diabetes,2021,12(2):138-148.
［54］　LIN K Y,HSIH W H,LIN Y B,WEN C Y,CHANG T J.Update in the epidemiology,risk factors,screening,and treatment of diabetic retinopathy［J］.J Diabetes Investig,2021,12(8):1322-1325.
［55］　CURTIS T M,GARDINER T,STITT A W.Microvascular lesions of diabetic retinopathy:clues towards understanding pathogenesis?［J］.Eye (Lond),2009,23(7):1496-1508.
［56］　KLEIN R,KNUDTSON M D,LEE K E,GANGNON R,KLEIN B E.The Wisconsin epidemiologic study of diabetic retinopathy XXIII:the twenty-five-year incidence of macular edema in persons with type 1 diabetes［J］.Ophthalmology,2009,116(3):497-503.
［57］　MAISONPIERRE P C,SURI C,JONES P F,BARTUNKOVA S A,RADZIEJEWSKI C,COMPTON D,et al.Angiopoietin-2,a natural antagonist for Tie2 that disrupts in vivo angiogenesis［J］.Science,1997,277(5322):55-60.
［58］　STEWART E A,SAKER S,WM A.Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro［J］.Exp Eye Res,2016,151:75-81.
［59］　KLAASSEN I,DE VRIES E W,VOGELS I,VAN KAMPEN A,BOSSCHA M,STEEL D,et al.Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes［J］.PLoS One,2017,12(11):e0187304.
［60］　SIM R,HERNNDEZ C,European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR).Neurodegeneration in the diabetic eye:new insights and therapeutic perspectives［J］.Trends Endocrinol Metab,2014,25(1):23-33.
［61］　HAMMES H P.Diabetic retinopathy:hyperglycaemia,oxidative stress and beyond［J］.Diabetologia,2018,61(1):29-38.
［62］　BARBER A J.Diabetic retinopathy:recent advances towards understanding neurodegeneration and vision loss［J］.Sci China Life Sci,2015,58(6):541-549.
［63］　NIAN S,LO A,MI Y,REN K,YANG D.Neurovascular unit in diabetic retinopathy:pathophysiological roles and potential therapeutical targets［J］.Eye Vis (London),2021,8(1):15.
［64］　SOHN E H,VAN DIJK H W,JIAO C,KOK P H,JEONG W,DEMIRKAYA N,et al.Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus［J］.Proc Natl Acad Sci U S A,2016,113(19):E2655-E2664.
［65］　ROSSINO M G,DAL MONTE M,CASINI G.Relationships between neurodegeneration and vascular damage in diabetic retinopathy［J］.Front Neurosci,2019,13:1172.
［66］　HSIAO C C,HSU H M,YANG C M,YANG C H.Correlation of retinal vascular perfusion density with dark adaptation in diabetic retinopathy［J］.Graefes Arch Clin Exp Ophthalmol,2019,257(7):1401-1410.
［67］　FRIZZIERO L,MIDENA G,LONGHIN E,BERTON M,TORRESIN T,PARROZZANI R,et al.Early retinal changes by OCT angiography and multifocal electroretinography in diabetes［J］.J Clin Med,2020,9(11):3514.
［68］　ASCHAUER J,POLLREISZ A,KARST S,HLSMANN M,HAJDU D,DATLINGER F,et al.Longitudinal analysis of microvascular perfusion and neurodegenerative changes in early type 2 diabetic retinal disease［J］.Br J Ophthalmol,2022,106(4):528-533.
［69］　SRINIVASAN S,SIVAPRASAD S,RAJALAKSHMI R,ANJANA R M,MALIK R A,KULOTHUNGAN V,et al.Early retinal functional alteration in relation to diabetes duration in patients with type 2 diabetes without diabetic retinopathy［J］.Sci Rep,2022,12(1):11422.
［70］　NEBBIOSO M,FEDERICI M,RUSCIANO D,EVANGELISTA M,PESCOSOLIDO N.Oxidative stress in preretinopathic diabetes subjects and antioxidants［J］.Diabetes Technol Ther,2012,14(3):257-263.
［71］　CHOUS A P,RICHER S P,GERSON J D,KOWLURU R A.The diabetes visual function supplement study (DiVFuSS)［J］.Br J Ophthalmol,2016,100(2):227-234.
［72］　KOWLURU R A,MISHRA M.Oxidative stress,mitochondrial damage and diabetic retinopathy［J］.Biochim Biophys Acta,2015,1852(11):2474-2483.
［73］　AN D,TAN B,YU D Y,BALARATNASINGAM C.Differentiating microaneurysm pathophysiology in diabetic retinopathy through objective analysis of capillary nonperfusion,inflammation,and pericytes［J］.Diabetes,2022,71(4):733-746.
［74］　WAN W,LONG Y,JIN X,LI Q,WAN W,LIU H,et al.Protective role of microRNA-200a in diabetic retinopathy through downregulation of PDLIM1［J］.J Inflamm Res,2021,14:2411-2424.
［75］　SPENCER B G,ESTEVEZ J J,LIU E,CRAIG J E,FINNIE J W.Pericytes,inflammation,and diabetic retinopathy［J］.Inflammopharmacology,2020,28(3):697-709.
［76］　WANG W,LO A.Diabetic retinopathy:pathophysiology and treatments［J］.Int J Mol Sci,2018,19(6):1816.
［77］　ALTMANN C,SCHMIDT M.The role of microglia in diabetic retinopathy:inflammation,microvasculature defects and neurodegeneration［J］.Int J Mol Sci,2018,19(1):110.
［78］　VUJOSEVIC S,MICERA A,BINI S,BERTON M,ESPOSITO G,MIDENA E.Aqueous humor biomarkers of müller cell activation in diabetic eyes［J］.Invest Ophthalmol Vis Sci,2015,56(6):3913-3918.
［79］　SIM-SERVAT O,HERNNDEZ C,SIM R.Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy［J］.Mediators Inflamm,2012,2012:872978.
［80］　HUANG J,ZHOU Q.Identification of the relationship between hub genes and immune cell infiltration in vascular endothelial cells of proliferative diabetic retinopathy using bioinformatics methods［J］.Dis Markers,2022,2022:7231046.
［81］　HU L,GONG C,CHEN X,ZHOU H,YAN J,HONG W.Associations between vascular endothelial growth factor gene polymorphisms and different types of diabetic retinopathy susceptibility:a systematic review and meta-analysis［J］.J Diabetes Res,2021,2021:7059139.
［82］　XIE X J,YANG Y M,JIANG J K,LU Y Q.Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk:a meta-analysis［J］.J Diabetes,2017,9(8):738-753.
［83］　KUMARI N,KARMAKAR A,GANESAN S K.Targeting epigenetic modifications as a potential therapeutic option for diabetic retinopathy［J］.J Cell Physiol,2020,235(3):1933-1947.
［84］　FORRESTER J V,KUFFOVA L,DELIBEGOVIC M.The role of inflammation in diabetic retinopathy ［J］.Front Immunol,2020,11:583687.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]吴岩 于靖 朱玮 李艳红 巴俊 栗莉 赵莼.2011年上海市闸北区和田路小学学生散光状态及相关因素分析[J].眼科新进展,2013,33(1):000.
[5]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[6]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[7]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[8]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[9]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[10]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[11]张立新 崔颖 孟倩丽 张敏 罗中伶 刘辉焜 朱国平 香淦媚 刘清洋 郭海科 郑洋 蔡晶晶. 广东省东莞市2型糖尿病患者盲与低视力患病率及原因分析[J].眼科新进展,2014,34(1):046.
[12]张敏 崔颖 孟倩丽 刘清洋 张立新 郭海科. 广东省东莞市糖尿病视网膜病变流行病学调查[J].眼科新进展,2014,34(3):260.

备注/Memo

备注/Memo:
国家自然科学基金青年项目（编号：82101152）
更新日期/Last Update: 2022-09-05